Thrombotic Thrombocytopenic Purpura in a Patient With Triple‐Negative Breast Cancer Treated With PD ‐ L1 Inhibition and Taxane Chemotherapy

Clinical Case Reports 2026 Open access

Read full text
Authors: Jason Ke, Albert C. Chong, Robert Y. Hsu, Anastasia Martynova, Noah Wald‐Dickler, Anishka D'souza, Caroline Piatek, G. In
DOI: 10.1002/ccr3.72247
Cited by: 2
References: 45

Abstract

Thrombocytopenic purpura (TTP) is a hematologic emergency that may occur with PD-L1 immunotherapy. New or worsening anemia and thrombocytopenia in patients started on PD-L1 inhibitors should raise suspicion for TTP and prompt workup for thrombotic microangiopathy.

Fields of Study & Subjects

Complement system in diseases Blood groups and transfusion Platelet Disorders and Treatments

Publication details

Journal / source
Clinical Case Reports
Publisher
Wiley
Volume
14
Issue
3
Pages
e72247–e72247
Publication date
1 March 2026
Language
EN